Development and In Vitro Cytotoxic Evaluation of Parenteral Docetaxel Lipid Nanoemulsions for Application in Cancer Treatment

References

1. 1.↵
   1. Strickley R. G.

   Solubulizing excipients in oral and injectable formulations. Pharm. Res. 2004, 21 (2), 201–230.

   OpenUrlCrossRefPubMedWeb of Science
2. 2.↵
   1. Engels F. K.,
   2. Mathot R. A.,
   3. Verweij J.

   Alternative drug formulations of docetaxel: a review. Anticancer Drugs 2007, 18 (2), 95–103.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Lundberg B.

   Preparation of drug-carrier emulsions stabilized with phosphatidylcholine-surfactant mixtures. J. Pharm. Sci. 1994, 83 (1), 72–75.

   OpenUrlPubMed
4. 4.↵
   1. Lundberg B. B.

   A submicron lipid emulsion coated with amphipathic polyethylene glycol for parenteral administration of paclitaxel (Taxol). J. Pharm. Pharmacol. 1997, 49 (1), 16–21.

   OpenUrlPubMedWeb of Science
5. 5.↵
   1. Nicolaos G.,
   2. Crauste-Manciet S.,
   3. Farinotti R.,
   4. Brossard D.

   Improvement of cefpodoxime proxetil oral absorption in rats by an oil-in-water submicron emulsion. Int. J. Pharm. 2003, 263 (1–2), 165–171.

   OpenUrlPubMed
6. 6.↵
   1. Jumaa M.,
   2. Müller B. W.

   The effect of oil components and homogenization conditions on the physicochemical properties and stability of parenteral fat emulsions. Int. J. Pharm. 1998, 163 (1–2), 81–89.

   OpenUrl
7. 7.↵
   1. Constantinides P. P.,
   2. Lambert K. J.,
   3. Tustian A. K.,
   4. Schneider B.,
   5. Lalji S.,
   6. Ma W.,
   7. Wentzel B.,
   8. Kessler D.,
   9. Worah D.,
   10. Quay S. C.

   Formulation development and antitumor activity of a filter-sterilizable emulsion of paclitaxel. Pharm. Res. 2000, 17 (2), 175–182.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Valenta C.,
   2. Wanka M.,
   3. Heidlas J.

   Evaluation of novel soya lecithin formulation for dermal use containing ketoprofen as a model drug. J. Controlled Release 2000, 63 (3), 165–173.

   OpenUrlCrossRefPubMedWeb of Science
9. 9.↵
   1. Nasirideen S.,
   2. Kas H. S.,
   3. Oner F.,
   4. Alpar R.,
   5. Hincal A. A.

   Naproxen incorporated lipid emulsions. I. Formulation and stability studies. J. Clin. Pharm. Ther. 1998, 23 (1), 57–65.

   OpenUrlPubMed
10. 10.↵
    1. Dietl H.

    Pharmaceutical Preparation Containing Cyclosporin(s) for Oral Administration and Process for Its Production. U.S. Patent 6,136,357, 1996.
11. 11.↵
    1. Mizushima Y.,
    2. Hamano T.,
    3. Yokoyama K.

    Tissue distribution and anti-inflammatory activity of corticosteroids incorporated in lipid emulsions. Ann. Rheum. Dis. 1982, 41 (3), 263–267.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Mizushima Y.,
    2. Yanagawa A.,
    3. Hoshi K.

    Prostaglandin E is more effective, when incorporated in lipid microspheres, for treatment of peripheral vascular diseases in man. J. Pharm. Pharmacol. 1983, 35 (10), 666–667.

    OpenUrlPubMedWeb of Science
13. 13.↵
    1. Varshika E.,
    2. Prabhakar K.,
    3. Kishan V.

    Preparation, characterization and in vivo pharmacodynamic evaluation of parenteral diclofenac submicron lipid emulsions. PDA J. Pharm. Sci. Tech. 2009, 63 (5), 380–389.

    OpenUrl
14. 14.↵
    1. Lee G. W. J.,
    2. Groves M. J.

    A pragmatic approach to the particle sizing of submicrometer emulsions using a laser nephalometer. Powder Technol. 1981, 28 (1), 49–54.

    OpenUrl
15. 15.↵
    1. Meyer S.,
    2. Berrut S.,
    3. Goodenough T. I. J.,
    4. Rajendram V. S.,
    5. Pinfield V. J.,
    6. Povey M. J. W.

    A comparative study of ultrasound and laser light diffraction techniques for particle size determination in dairy beverages. Meas. Sci. Technol. 2006, 17 (2), 289–297.

    OpenUrl
16. 16.↵
    1. Lieberman H. A.,
    2. Rieger M. M.,
    3. Banker G. S.

    Pharmaceutical Dosage Forms: Disperse Systems. Marcel Dekker, Inc.: New York, 1988; Vol. 1.
17. 17.↵
    1. Krishna G.,
    2. Wood G. C.,
    3. Sheth B. B.

    Improving emulsification efficacy of lecithin by formulation design. I: Effect of adding a secondary surfactant. PDA J. Pharm. Sci. Technol. 1998, 52 (6), 331–336.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    1. Rouini M. R.,
    2. Lotfolahi A.,
    3. Stewart D. J.,
    4. Molepo J. M.,
    5. Shirazi F. H.,
    6. Vergniol J. C.,
    7. Tomiak E.,
    8. Delorme F.,
    9. Vernillet L.,
    10. Giguere M.,
    11. Goel R.

    A rapid reversed phase high performance liquid chromatographic method for the determination of docetaxel (Taxotere) in human plasma using a column switching technique. J. Pharm. Biomed. Anal. 1998, 17 (8), 1243–1247.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Tolnai S.

    A method for viable cell count. Methods in Cell Science 1975, 1 (1), 37–38.

    OpenUrl
20. 20.↵
    1. Shotton E.,
    2. Davis S. S.

    A note on the stability of emulsion on high dilution. J. Pharm. Pharmacol. 1968, 20 (11), 825–829.

    OpenUrlPubMed